Bioepuivalence Study for the Safety and the Pharmacokinetics of DWJ1589 and DWC202315

Bioepuivalence Study for the Safety and the Pharmacokinetics of DWJ1589 and DWC202315 in Healthy Adult Volunteers Under Fasting Conditions

This study aims to evaluate the safety and pharmacokinetic characteristics after administration of DWJ1589 and DWC202315 in healty adult volunteers.

The study design is a Randomized, Open-label, Oral, Single-dose, 2 × 4 crossover study. The patients were randomly assigned to each group. Primary endpoint was Cmax and AUClast of DWJ1589 and DWC202315. Secondary endpoints were AUCinf, AUClast/AUCinf, Tmax and t1/2 of DWJ1589 and DWC202315.

Inclusion Criteria:

• Over 19 year old
• Healthy adult volunteers

Exclusion Criteria:

• with a history of mental disorder
• For female volunteers, those who are suspected of being pregnant or lactating